Esperion Therapeutics, Inc.

Esperion Therapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on oral, once-daily, non-statin medicines for lowering LDL-C and reducing cardiovascular risk. Its core business is the commercialization of NEXLETOL and NEXLIZET in the United States, supported by ex-U.S. partnerships, supply agreements, and a preclinical pipeline built around next-generation ACLY inhibitors.

15,0 %

−5,6 %

+21,3 %

1.54

1.19

— Esperion Therapeutics, Inc.
%
Commercial cardiovascular medicines85% FDA-approved oral therapies sold in the U.S. for LDL-C lowering and cardiovascular risk reduction.
International collaboration revenue10% Royalties and supply revenue from ex-U.S. partners commercializing licensed products.
Preclinical pipeline0% Early-stage ACLY inhibitor research programs that may expand the product base over time.
Other partnership and milestone income5% Milestones and other contractual payments tied to collaboration agreements.

Esperion sells primarily into the U.S. cardiovascular and lipid-management market, where physicians prescribe its...

  • U.S. prescribers and patientsprimary

    Physicians prescribe NEXLETOL and NEXLIZET for patients who need oral LDL-C lowering beyond statins or ezetimibe.

  • Ex-U.S. collaboration partnerssecondary

    Partners such as DSE, DS, and Otsuka buy API or bulk tablets and commercialize licensed products in their territories.

  • Cardiovascular specialty marketprimary

    Cardiologists and lipid specialists use the products for patients with persistent LDL-C elevation and high CVD risk.

  • Primary care marketsecondary

    Primary care physicians represent a broader prescribing base for patients managed outside specialty clinics.

Esperion is commercially anchored in the United States, where NEXLETOL and NEXLIZET are sold directly...

  • •United States is the core commercial market for NEXLETOL and NEXLIZET
  • •Europe contributes through partner commercialization and royalties
  • •Japan and other Asian territories are served through collaboration agreements
  • •Esperion supplies API and bulk tablets to ex-U.S. partners
  • •International revenue depends on partner execution and local reimbursement

Esperion’s strategy is to grow U.S. sales of NEXLETOL and NEXLIZET through label expansion, promotion, and broader...

01
Grow U.S. product salesshort-term

The company depends heavily on NEXLETOL and NEXLIZET to generate revenue and move toward profitability.

02
Scale partner-led international revenuemedium-term

Partnerships can extend the franchise into Europe and other territories without full direct commercialization costs.

03
Advance preclinical pipelinemedium-term

New ACLY inhibitors could reduce dependence on the current two-product franchise.

04
Broaden the company through business developmentlong-term

Additional products could better utilize the existing commercial organization and diversify revenue.

Esperion is highly exposed to execution risk because it depends almost entirely on two products and must keep growing...

high

Concentration in two products

Most commercial value comes from bempedoic acid and the bempedoic acid/ezetimibe franchise, so any demand or safety issue would have an outsized effect.

Scope
NEXLETOL and NEXLIZET
Materiality
high
high

Intense lipid-therapy competition

The market includes inexpensive generics and strong branded alternatives, which can limit uptake and pricing power.

Scope
Statins, ezetimibe, PCSK9 inhibitors, Vascepa
Materiality
high
high

Financing and liquidity pressure

The company has a history of operating losses and may need external capital if sales or milestones do not cover cash needs.

Scope
Equity, debt, royalty-based financing
Materiality
high
medium

Partner dependence

International revenue relies on collaborators to commercialize products, manage reimbursement, and drive sales in their territories.

Scope
DSE, DS, Otsuka and other ex-U.S. partners
Materiality
medium
medium

Cybersecurity and IT disruption

Commercial, clinical, and partner operations depend on internal and third-party systems that could be compromised.

Scope
Commercialization and development programs
Materiality
medium
Net product sales deductions
Can materially change reported product sales and quarterly comparability
Collaboration revenue recognition
Can create timing differences between shipments, partner sales, and reported revenue
Royalty purchase agreement and milestone estimates
Affects revenue timing and other income/expense
Debt extinguishment and exchange transactions
Can cause large one-time non-operating gains or losses

EXELIXIS, INC.

EXEL · Biological Products, (No Diagnostic Substances)

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

BICYCLE THERAPEUTICS PLC

BCYC · Pharmaceutical Preparations

Lexeo Therapeutics, Inc.

LXEO · Biological Products, (No Diagnostic Substances)

Xencor Inc

XNCR · Pharmaceutical Preparations

Aclaris Therapeutics, Inc.

ACRS · Pharmaceutical Preparations

: 28/04/2026